Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because T cells specific for these antigens are present with low frequency and may be rendered anergic by the tumors that express them, we expanded LMP-cytotoxic T lymphocytes (CTLs) from patients with lymphoma using autologous dendritic cells and EBV-transformed B-lymphoblastoid cell lines transduced with an adenoviral vector expressing either LMP2 alone (n = 17) or both LMP2 and ΔLMP1 (n = 33).
|
24344220 |
2014 |
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thirty-bp deletion in the LMP-1 carboxy terminal region was demonstrated in the virus-infected lymphoma, but not in the squamous cell carcinomas.
|
11432667 |
2001 |
Childhood Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In all four patients, the lymphoma was associated with Epstein-Barr virus infection, detected by EBER in situ hybridization and the latency I phenotype as defined by lack of expression of LMP1.
|
15104301 |
2004 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Using a panel of transfected sublines of the B-lymphoma line BJAB expressing the viral genes associated with latent infection, we show that the EBV nuclear antigens, EBNA-1 and EBNA-3C, and the latent membrane protein 1, LMP-1, independently promote genomic instability, as detected by nonclonal chromosomal aberrations, DNA breaks and phosphorylation of histone H2AX.
|
19718051 |
2009 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Analysis of EBV gene transfectants of the B lymphoma lines BJAB and BL41 showed that the virus-encoded latent membrane protein-1 (LMP1), which is one of several EBV antigens expressed in group III but not in group I cells, was uniquely able to up-regulate expression both of the Tap proteins and HLA class I.
|
7774641 |
1995 |
Childhood Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Differences in EBV association and LMP-1 expression were found between a major group of HIV-associated systemic NHL with blastic cell morphology, including SNCC lymphoma and its variants, and anaplastic cell lymphomas.
|
8394878 |
1993 |
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The present study revealed a high frequency of EBV association, and a high frequency of 30-bp deletion in the LMP-1 gene in the virus in the present series of lymphoma.
|
14989738 |
2004 |
Childhood Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, IL-10 could induce the expression of LMP-1 in tonsillar B cells infected with the nontransforming, EBNA-2-deficient EBV strain P3HR1 and enhance LMP-1 expression in 2 EBV-positive NK lymphoma lines.
|
16332968 |
2006 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we report that the bioactivity of antcin H, an analog of the JAK2 inhibitor zhankuic acid A (ZAA), inhibits LMP1-induced JAK/STAT related signaling and induces lymphoma cell line apoptosis.
|
30277103 |
2019 |
Childhood Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The AS-oligo to LMP-1 suppressed LMP-1 mRNA and protein expression in two EBV-positive NK cell lymphoma cell lines, as well as in an EBV-transformed B-cell line (CMG-1).
|
11472349 |
2001 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
LMP1 effects were also evaluated in the EBV-negative B-lymphoma cell line BL41 and the EBV-positive Burkitt's lymphoma cell line, Daudi (Daudi is deleted for EBNA-2 and does not express LMP).
|
2157887 |
1990 |
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The LMP1 deletion variant and the wild-type sequence were also identified within peripheral blood mononuclear cells of the EBV-seroconverted kidney recipient 20 months after lymphoma therapy.
|
9381534 |
1997 |
Childhood Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The lymphoma fails to express the EBV transforming proteins EBNA-2 and LMP-1, whereas it expresses EBNA-1 (latency I phenotype).
|
10673744 |
2000 |
Childhood Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, transfection with LMP1 expression vector into a human B lymphoma cell line, Daudi, led to p40 production with nuclear factor (NF)-kappaB activation.
|
9837745 |
1998 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Polymerase chain reaction amplification and in situ hybridization revealed that lymphoma and carcinoma cells contained the EBV LMP1 and EBERs genes.
|
9829857 |
1998 |
Childhood Lymphoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A comparative sequence analysis of the fingerprint LMP1 region identified in donor lymphocytes and lymphoma was performed.
|
11502981 |
2001 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) is crucial for B cell transformation and oncogenesis of other EBV-related malignancies, such as nasopharyngeal carcinoma and T/NK lymphoma.
|
26819314 |
2016 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The LMP1-mediated activation of NF-kappaB may contribute to the specific activation of c-Rel and lead to the increased development of lymphoma in the LMP1 transgenic mice.
|
16247482 |
2006 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although the latent membrane protein-1 (LMP1) of the Epstein-Barr virus (EBV) is believed to be important for the transformation of germinal centre (GC) B cells, the precise contribution of this viral oncogene to lymphoma development is poorly understood.
|
18566961 |
2008 |
Childhood Lymphoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The EBV oncogene LMP1 protects lymphoma cells from cell death through the collagen-mediated activation of DDR1.
|
24136166 |
2013 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The EBV latent genes, latent membrane protein 1 (LMP1) and the EBV nuclear antigen 2 (EBNA2), were detected by immunohistochemistry in the Wiskott-Aldrich lymphoma but not in an EBV-positive Burkitt's lymphoma, implying that host immune factors could influence EBV gene expression.
|
8112728 |
1994 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The oncogenic latent membrane protein 1 (LMP1) of Epstein-Barr virus (EBV) is involved in the pathogenesis of human nasopharyngeal carcinoma (NPC) and lymphoma.
|
23939952 |
2014 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Epstein-Barr virus latent membrane protein 1 (LMP-1) is essential for virus-induced B cell immortalization and can protect B lymphoma cell lines from apoptosis signals in vitro via induction of cellular Bcl-2 expression.
|
9367385 |
1997 |
Childhood Lymphoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Induction of CD44 expression by the Epstein-Barr virus latent membrane protein LMP1 is associated with lymphoma dissemination.
|
7537255 |
1995 |
Childhood Lymphoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Further, transient Flag-LMP1 expression in a B-lymphoma cell line transduces signals that upregulate TRAF1 levels but does not alter JAK3 levels or activation state.
|
11739714 |
2002 |